(Q36392552)

13 August 2017

1 reference

title

An industry perspective on the NIMH consensus statement on negative symptoms (English)

1 reference

13 August 2017

Larry Alphs

1

1 reference

PMC publication ID

2632231

13 August 2017

language of work or name

English

0 references

publication date

9 February 2006

1 reference

13 August 2017

Schizophrenia Bulletin

1 reference

13 August 2017

32

1 reference

13 August 2017

2

1 reference

13 August 2017

225-230

1 reference

The NIMH-MATRICS consensus statement on negative symptoms

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

Food and Drug Administration perspective on negative symptoms in schizophrenia as a target for a drug treatment claim

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

Negative symptoms in schizophrenia. Definition and reliability

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

The Scale for the Assessment of Negative Symptoms (SANS): conceptual and theoretical foundations

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

Validation of the 16-item Negative Symptom Assessment.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

Quetiapine has equivalent efficacy and superior tolerability to risperidone in the treatment of schizophrenia with predominantly negative symptoms

28 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

Predicting quality of life from symptomatology in schizophrenia at exacerbation and stabilization.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

A comparison of instrument sensitivity to negative symptom change.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

Factor structure of the negative symptom assessment.

21 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2632231

The negative symptom assessment: a new instrument to assess negative symptoms of schizophrenia

21 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16469940

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16469940

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Risperidone for exclusively negative symptoms

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/16469940

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1093/SCHBUL/SBJ056

1 reference

13 August 2017

1 reference

PMC publication ID

2632231

13 August 2017

PubMed publication ID

16469940

1 reference

PMC publication ID

2632231